3-Chloro-5-[2-chloro-5-[(1-methylbenzimidazol-2-yl)methoxy]phenoxy]benzonitrile → 2-(Chloromethyl)-1-methylbenzimidazole
Reaktionsgleichung
[Cl:1]C1C=C(C=C(OC2C=C(O)C=CC=2Cl)C=1)C#N.ClC1C=C(C=C(OC2C=C(O[CH2:36][C:37]3[N:41]([CH3:42])[C:40]4[CH:43]=[CH:44][CH:45]=[CH:46][C:39]=4[N:38]=3)C=CC=2Cl)C=1)C#N>>[Cl:1][CH2:36][C:37]1[N:41]([CH3:42])[C:40]2[CH:43]=[CH:44][CH:45]=[CH:46][C:39]=2[N:38]=1Komponenten
3
Versuchsvorschrift
In a manner similar to that described in Example 1 above for the synthesis of 1-2, from 50 mg (0.18 mmol) of 3-chloro-5-(2-chloro-5-hydroxyphenoxy)benzonitrile (C-3) and 33 mg (0.18 mmol) of 2-(chloromethyl)-1-methyl-1H-benzimidazole (31-1) was obtained the desired product 31-2 (TFA salt) as an amorphous fluffy white powder. MS M+=424. 1H NMR (CDCl3): 4.03 (s, 3H), 5.66 (s, 2H), 6.88 (d, 1H), 6.99 (m, 1H), 7.03 (dd, 1H), 7.14 (m, 1H), 7.35 (m, 1H), 7.45 (d, 1H), 7.49 (m, 3H), 7.93 (d, 1H).